Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells 18,900 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 18,900 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $28.72, for a total transaction of $542,808.00. Following the completion of the transaction, the chief operating officer owned 49,163 shares of the company's stock, valued at $1,411,961.36. This trade represents a 27.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.28, for a total transaction of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42.
• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.38, for a total transaction of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.46, for a total transaction of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $26.41, for a total transaction of $316,920.00.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded up $0.18 during midday trading on Friday, reaching $29.02. 841,396 shares of the company's stock traded hands, compared to its average volume of 558,527. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $30.69. The company has a market cap of $2.12 billion, a P/E ratio of -116.08 and a beta of 0.05. The company has a fifty day simple moving average of $27.90 and a two-hundred day simple moving average of $23.45.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The company had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. During the same period in the previous year, the business earned ($0.25) EPS. Kiniksa Pharmaceuticals International's quarterly revenue was up 72.5% on a year-over-year basis. As a group, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently made changes to their positions in the company. Braidwell LP grew its position in shares of Kiniksa Pharmaceuticals International by 19.3% in the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock valued at $68,289,000 after buying an additional 557,934 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock valued at $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Acadian Asset Management LLC grew its position in Kiniksa Pharmaceuticals International by 170.3% in the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after purchasing an additional 651,700 shares during the last quarter. Millennium Management LLC boosted its holdings in Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after buying an additional 67,452 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in Kiniksa Pharmaceuticals International by 7.3% in the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after buying an additional 54,361 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on KNSA. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday, July 6th. Wedbush reissued an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Finally, Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $39.33.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.